Based on new data from clinical trials, the U.S. Food and Drug Administration (FDA) has concluded that a diabetes medication has an increased risk of amputation. Canagliflozin (known by the brand names Invokana, Invokamet, and Invokamet XR) was approved for sale in the U.S. in 2013. New warnings will be added to the labels.
The purpose of diabetes medication is to lower the blood sugar level and reduce complications such as infection and amputation. Nevertheless, amputations occurred about twice as often in patients treated with canagliflozin compared to patients treated with placebo.
Amputations of the toe and middle of the foot were the most common. However, amputations of the leg also occurred.
Patients taking canagliflozin should notify their doctor right away if a new pain, sore, or infection develops in the leg or foot. Factors that predispose a diabetic to amputation include poor blood flow and numbness in feet.
The complications of diabetes are complex and costly. Dr. Steven Miller has extensive experiencing in treating diabetic foot ailments and preventing amputation. To schedule a comprehensive foot assessment with Dr. Miller, please call our office at (847) 675-3400 or CLICK HERE.